The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences Inc. participated in and sponsored the SADS Foundation’s Challenging Cases in Inherited Arrhythmias Symposium and Reception last week.
The company emphasized its commitment to advancing research and raising awareness about genetic heart rhythm conditions. Attending the event underscores Solid Biosciences Inc.'s engagement with leading foundations addressing cardiac genetics. Details of the collaboration and future projects were not disclosed.
View post on X Loading...
Earlier this year, Solid Biosciences announced advancements in precision gene therapy at a major symposium, including new targeting strategies. The company also initiated human trials for its SGT-212 gene therapy, addressing both neuromuscular and cardiac conditions such as Friedreich ataxia in clinical studies. These initiatives highlight the company's focus on genetic approaches to treat inherited disorders.